Silence Therapeutics (SLN) Gains from Investment Securities: 2022-2025
Historic Gains from Investment Securities for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to -$2.9 million.
- Silence Therapeutics' Gains from Investment Securities fell 929.18% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year decrease of 424.47%. This contributed to the annual value of $17.5 million for FY2024, which is 442.60% up from last year.
- Per Silence Therapeutics' latest filing, its Gains from Investment Securities stood at -$2.9 million for Q3 2025, which was down 588.57% from -$420,000 recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Gains from Investment Securities ranged from a high of $19.7 million in Q4 2023 and a low of -$2.9 million during Q3 2025.
- For the 3-year period, Silence Therapeutics' Gains from Investment Securities averaged around $2.9 million, with its median value being -$138,500 (2024).
- Per our database at Business Quant, Silence Therapeutics' Gains from Investment Securities skyrocketed by 44.97% in 2023 and then crashed by 929.18% in 2025.
- Over the past 4 years, Silence Therapeutics' Gains from Investment Securities (MRQ) stood at $13.6 million in 2022, then skyrocketed by 44.97% to $19.7 million in 2023, then plummeted by 62.61% to $7.4 million in 2024, then plummeted by 139.30% to -$2.9 million in 2025.
- Its Gains from Investment Securities was -$2.9 million in Q3 2025, compared to -$420,000 in Q2 2025 and -$89,000 in Q1 2025.